Aktuellt
SENASTE
Fluoguide reported strong cost control in Q3, as usual, and reported progress with experts and regulators on the design of the high-grade glioma (HGG) trial. In addition, impressive results of FG001 in head and neck cancer were published, with all 16 patients' cancers lighting up and a high tumour-to-background ratio. A second head and neck cancer trial is planned to start in Q1/25, with data in H2/25, and Fluoguide expects the HGG trial design to be finalized in H2/25.
LÄS MER
